AKTX Stock Summary and Trading Ideas (Akari Therapeutics PLC - American Depositary Shares | NASDAQ:AKTX)

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.

As of May 15, 2026, AKTX stock price declined to $3.49 with 12,987 million shares trading.

AKTX has a beta of 1.94, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.05 to the broad based SPY ETF.

AKTX has a market cap of $124.73 million. This is considered a Micro Cap stock.

In the last 3 years, AKTX traded as high as $220.00 and as low as $3.02.

AKTX has underperformed the market in the last year with a price return of -93.4% while the SPY ETF gained +26.4%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -62.6% and -36.2%, respectively, while the SPY returned +8.7% and +2.6%, respectively.

AKTX support price is $3.28 and resistance is $4.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.